Anti-EGFR Monoclonal Antibody (Cetuximab) (FITC Conjugate)

產(chǎn)品型號：S0B1839

更新時(shí)間：2025-07-15

廠商性質(zhì)：生產(chǎn)廠家

訪問量：132

服務(wù)熱線

15855403091

立即咨詢

產(chǎn)品分類

PRODUCT CLASSIFICATION

抗體/抗原

ELISA試劑盒抗體試劑盒二抗試劑盒二抗其它流式抗體瓊脂糖/磁珠偶聯(lián)抗體抗Payload抗體泛修飾抗體標(biāo)簽/內(nèi)參抗體功能性抗體 Biosimilar抗體偶聯(lián)抗體配對抗體病理/IHC抗體

查看全部產(chǎn)品

相關(guān)文章

PLA技術(shù)+蛋白翻譯后修飾（PTMs）研究，蛋白研究新CP！

細(xì)胞外基質(zhì)（ECM）對上皮-間充質(zhì)轉(zhuǎn)化（EMT）作用影響解析

T細(xì)胞激活試劑盒，促進(jìn)免疫細(xì)胞信號傳導(dǎo)研究

Fibronectin：細(xì)胞培養(yǎng)的黏附大師

產(chǎn)品介紹

Cetuximab is a monoclonal antibody that inhibits the epidermal growth factor receptor （EGFR） which is present on the surface of some cancer cells. Cetuximab binds to the receptor, preventing epidermal growth factor （EGF） from binding to it and stimulating growth of the cancer cells. Cetuximab is used to treat squamous cell cancer of the head and neck. Cetuximab is commonly used alongside chemotherapy as a first line approach to cancer that has spread or is recurring. It is also used alongside radiation therapy in localized disease. Patients with metastatic colorectal cancer that expresses EGFR may be treated with cetuximab in combination with chemotherapy or cetuximab may be given as a single therapy to patients who have failed to respond to irinotecan- and oxaliplatin-based regimens.

上一個(gè)：S0M1037STING pathway MiniAb Kit(Mouse）